Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Feb 28, 2018 at 9:10 AM EST

Short Sellers Hike Bets in Major Pharma

The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Chris Lange | Feb 27, 2018 at 11:00 AM EST

Could Data Breaches Break Up the Akorn Aquisition?

Akorn saw its shares crater on Tuesday after some doubts were cast on its potential acquisition by German health care…

Trey Thoelcke | Feb 23, 2018 at 10:20 AM EST

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

Cancer immunotherapy approaches have attracted the attention of Big Pharma in the past. New technology from Stanford University probably will…

Jon C. Ogg | Feb 22, 2018 at 2:52 PM EST

Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?

If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.

Chris Lange | Feb 22, 2018 at 10:20 AM EST

Meet Gilead and Sangamo’s Next Big Cancer Collaboration

Sangamo Therapeutics saw its shares make a solid gain on Thursday after the company announced that it had entered into…

Chris Lange | Feb 21, 2018 at 11:30 AM EST

Dynavax Pops With CDC Recommendation

Dynavax Technologies saw its shares make a handy gain early on Wednesday after the company announced that it received a…

Chris Lange | Feb 21, 2018 at 8:35 AM EST

Why Tetraphase Pharmaceuticals Shares Are Popping

Tetraphase Pharmaceuticals saw its shares make a solid gain early on Wednesday after the company announced an exclusive licensing agreement…

Chris Lange | Feb 20, 2018 at 11:00 AM EST

Aimmune’s Late Stage Trial Win Not Enough for Investors

Aimmune Therapeutics shares initially made a handy gain on Tuesday after the company reported data from its late-stage peanut allergy…

Chris Lange | Feb 19, 2018 at 10:10 AM EST

More Health Care Catalysts to Watch For by the End of February

Here 24/7 Wall St. has included a calendar of a few of the biggest companies expecting clinical trial and FDA…

Jon C. Ogg | Feb 15, 2018 at 1:20 PM EST

AbbVie Delivers on Promise of Higher Dividend and Stronger Stock Buybacks

AbbVie is joining the companies raising their shareholder rewards. The pharmaceutical products maker has announced how it will further commit…

Chris Lange | Feb 15, 2018 at 11:25 AM EST

Moleculin Biotech Explodes on Breakthrough Cancer Treatment

Moleculin Biotech watched its shares climb on Thursday after the company announced a new breakthrough for cancer treatment.

Chris Lange | Feb 15, 2018 at 10:45 AM EST

Why AMAG Pharmaceuticals Is Soaring

AMAG Pharmaceuticals saw its shares skyrocket early on Thursday after the company announced that it received an FDA approval.

Chris Lange | Feb 14, 2018 at 9:55 AM EST

Why Tetraphase Pharmaceuticals Is Getting Cut in Half

Tetraphase Pharmaceuticals saw its shares get cut in half on Wednesday after the firm provided an update on its late-stage…

Lee Jackson | Feb 14, 2018 at 8:10 AM EST

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

With indiscriminate selling absolutely punishing some of the top large cap biotech stocks, one analyst says now is the time…

Paul Ausick | Feb 13, 2018 at 2:17 PM EST

US Opioid Crisis Cost: $1 Trillion and Counting

The U.S. opioid crisis has cost $1 trillion in lost wages, productivity, and other expenditures since 2001. The cost is…

1 … 141 142 143 144 145 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Hike Bets in Major Pharma

Could Data Breaches Break Up the Akorn Aquisition?

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?

Meet Gilead and Sangamo’s Next Big Cancer Collaboration

Dynavax Pops With CDC Recommendation

Why Tetraphase Pharmaceuticals Shares Are Popping

Aimmune’s Late Stage Trial Win Not Enough for Investors

More Health Care Catalysts to Watch For by the End of February

AbbVie Delivers on Promise of Higher Dividend and Stronger Stock Buybacks

Moleculin Biotech Explodes on Breakthrough Cancer Treatment

Why AMAG Pharmaceuticals Is Soaring

Why Tetraphase Pharmaceuticals Is Getting Cut in Half

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

US Opioid Crisis Cost: $1 Trillion and Counting

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers Hike Bets in Major Pharma

Could Data Breaches Break Up the Akorn Aquisition?

Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid

Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?

Meet Gilead and Sangamo’s Next Big Cancer Collaboration

Dynavax Pops With CDC Recommendation

Why Tetraphase Pharmaceuticals Shares Are Popping

Aimmune’s Late Stage Trial Win Not Enough for Investors

More Health Care Catalysts to Watch For by the End of February

AbbVie Delivers on Promise of Higher Dividend and Stronger Stock Buybacks

Moleculin Biotech Explodes on Breakthrough Cancer Treatment

Why AMAG Pharmaceuticals Is Soaring

Why Tetraphase Pharmaceuticals Is Getting Cut in Half

Top Analyst Has 3 Large Cap Biotechs to Buy as Massive Selling Subsides

US Opioid Crisis Cost: $1 Trillion and Counting

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how